These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31563242)

  • 21. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
    Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
    Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
    Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
    Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability.
    Kauke T; Oberhauser C; Lin V; Coenen M; Fischereder M; Dick A; Schoenermarck U; Guba M; Andrassy J; Werner J; Meiser B; Angele M; Stangl M; Habicht A
    Transpl Int; 2017 Apr; 30(4):360-370. PubMed ID: 27862352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influences of Pre-formed Donor-Specific Anti-Human Leukocyte Antigen Antibodies in Living-Donor Renal Transplantation: Results With Graft Immunocomplex Capture Fluorescence Analysis.
    Nakamura T; Ushigome H; Watabe K; Imanishi Y; Masuda K; Matsuyama T; Harada S; Koshino K; Iida T; Nobori S; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):955-958. PubMed ID: 28583566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcineurin inhibitor-free monotherapy in human leukocyte antigen–identical live donor renal transplantation.
    Venot M; Abboud I; Duboust A; Michel C; Suberbielle C; Vérine J; Flamant M; Morelon E; Glotz D; Peraldi MN
    Transplantation; 2011 Feb; 91(3):330-3. PubMed ID: 21344733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
    Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
    Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation.
    Alagoz S; Seyahi N
    Transplant Proc; 2019 Sep; 51(7):2302-2307. PubMed ID: 31358448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
    Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
    Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols.
    Chkhotua AB; Klein T; Shabtai E; Yussim A; Bar-Nathan N; Shaharabani E; Lustig S; Mor E
    Urology; 2003 Dec; 62(6):1002-6. PubMed ID: 14665344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
    Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
    Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
    Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.